Comparison of indications and results of prenatal invasive diagnostic tests before and after the implementation of the use of cell-free fetal DNA: a tertiary referral center experience

dc.contributor.authorOkmen, Firat
dc.contributor.authorEkici, Huseyin
dc.contributor.authorHortu, Ismet
dc.contributor.authorImamoglu, Metehan
dc.contributor.authorArican, Duygu
dc.contributor.authorAkn, Haluk
dc.contributor.authorSagol, Sermet
dc.date.accessioned2020-12-01T12:01:14Z
dc.date.available2020-12-01T12:01:14Z
dc.date.issued2020
dc.departmentEge Üniversitesien_US
dc.description.abstractPurpose in this study, we aimed to compare the changes in the number, yield, and the percentage of karyotyping indications of the invasive prenatal diagnostic tests between the periods before and after cell-free fetal DNA was introduced to clinical use. Method the number of invasive prenatal diagnostic procedures such as amniocentesis and chorionic villus sampling, indication percentages and karyotype results in the periods before (January 1, 2009-December 31, 2010), (n = 1412) and after (January 1, 2016-December 31, 2017), and (n = 593) the introduction of cell-free fetal DNA was retrospectively evaluated. Results When compared with the period before cell-free fetal DNA came into clinical use, the number of invasive prenatal diagnostic tests decreased by 58% while their yield was found to have increased (4.4% vs. 10.3%) in the period after cell-free DNA began to be used (p < 0.001). While there was a decrease in the indications due to advanced maternal age, an increase was found in ultrasonography indications for structural anomaly and the risk of a single-gene disorder (p < 0.001). Amniocentesis rate was found to have decreased in invasive prenatal diagnostic procedure types, while an increase was reported in CVS rates (p < 0.001). Conclusions Invasive prenatal diagnosis gradually decreases over the years, but the yield of invasive prenatal diagnostic tests increases. in parallel with the rapid development of modern molecular technologies and cheaper and easier access to the tests, we think that the number of invasive prenatal diagnostic tests will experience a more dramatic decrease in the following years.en_US
dc.identifier.doi10.1007/s10815-020-01825-3en_US
dc.identifier.endpage2024en_US
dc.identifier.issn1058-0468
dc.identifier.issn1573-7330
dc.identifier.issue8en_US
dc.identifier.pmid32440934en_US
dc.identifier.scopus2-s2.0-85085332947en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage2019en_US
dc.identifier.urihttps://doi.org/10.1007/s10815-020-01825-3
dc.identifier.urihttps://hdl.handle.net/11454/62361
dc.identifier.volume37en_US
dc.identifier.wosWOS:000534728900002en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringer/Plenum Publishersen_US
dc.relation.ispartofJournal of Assisted Reproduction and Geneticsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectCell free-fetal DNAen_US
dc.subjectPrenatal invasive testen_US
dc.subjectAneuploidyen_US
dc.subjectChromosomal abnormalityen_US
dc.titleComparison of indications and results of prenatal invasive diagnostic tests before and after the implementation of the use of cell-free fetal DNA: a tertiary referral center experienceen_US
dc.typeArticleen_US

Dosyalar